Literature DB >> 15749746

Strain-dependent beta-adrenergic receptor function influences myocardial responses to isoproterenol stimulation in mice.

Michael D Faulx1, Paul Ernsberger, Dorothy Vatner, Robert D Hoffman, William Lewis, Ryan Strachan, Brian D Hoit.   

Abstract

Recently, we showed that compared with the A/J inbred mouse strain, C57BL/6J (B6) mice have an athlete's cardiac phenotype. We postulated that strain differences would result in greater left ventricular (LV) hypertrophy in response to isoproterenol in B6 than A/J mice and tested the hypothesis that a differential response could be explained partly by differences in beta-adrenergic receptor (beta-AR) density and/or coupling. A/J and B6 mice were randomized to receive daily isoproterenol (100 mg/kg sc) or isovolumic vehicle for 5 days. Animals were studied using echocardiography, tail-cuff blood pressure, histopathology, beta-AR density and percent high-affinity binding, and basal and stimulated adenylyl cyclase activities. One hundred twenty-eight mice (66 A/J and 62 B6) were studied. Isoproterenol-treated A/J mice demonstrated greater percent increases in echocardiographic LV mass/body weight (97 +/- 11 vs. 20 +/- 10%, P = 0.001) and in gravimetric heart mass/body weight versus same-strain controls than B6 mice. Histopathology scores (a composite of myocyte hypertrophy, nuclear changes, fibrosis, and calcification) were greater in isoproterenol-treated A/J vs. B6 mice (2.8 +/- 0.2 vs.1.9 +/- 0.3, P < 0.05), as was quantitation of myocyte damage (22.3 +/- 11.5 vs. 4.3 +/- 3.5%). Interstrain differences in basal beta-AR density, high-affinity binding, and adenylyl cyclase activity were not significant. However, whereas isoproterenol-treated A/J mice showed nonsignificant increases in all beta-AR activity measures, isoproterenol-treated B6 mice had lower beta-AR density (57 +/- 6 vs. 83 +/- 8 fmol/mg, P < 0.05), percent high-affinity binding (15 +/- 2 vs. 26 +/- 3%, P < 0.005), and GTP + isoproterenol-stimulated adenylyl cyclase activity (10 +/- 1.1 vs. 5.8 +/- 1.5 pmol cAMP.mg(-1).min(-1)) compared with controls. High-dose, short-term isoproterenol produces greater macro- and microscopic cardiac hypertrophy and injury in A/J than B6 mice. A/J mice, unlike B6 mice, do not experience beta-AR downregulation or uncoupling in response to isoproterenol. Abnormalities in beta-adrenergic regulation may contribute to strain-related differences in the vulnerability to isoproterenol-induced cardiac changes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15749746     DOI: 10.1152/ajpheart.00636.2004

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  30 in total

1.  Fibroblast Growth Factor 2 Mediates Isoproterenol-induced Cardiac Hypertrophy through Activation of the Extracellular Regulated Kinase.

Authors:  Stacey L House; Brian E House; Betty Glascock; Thomas Kimball; Eyad Nusayr; Jo El J Schultz; Thomas Doetschman
Journal:  Mol Cell Pharmacol       Date:  2010

Review 2.  β-Adrenergic receptor subtype signaling in heart: from bench to bedside.

Authors:  Anthony Yiu Ho Woo; Rui-ping Xiao
Journal:  Acta Pharmacol Sin       Date:  2012-01-30       Impact factor: 6.150

3.  Akt2 deficiency promotes cardiac induction of Rab4a and myocardial β-adrenergic hypersensitivity.

Authors:  Sharon Etzion; Yoram Etzion; Brian DeBosch; Peter A Crawford; Anthony J Muslin
Journal:  J Mol Cell Cardiol       Date:  2010-08-20       Impact factor: 5.000

4.  The role of E2F1 in the development of hypertrophic cardiomyopathy.

Authors:  Julie A Wolfram; Anna Liner; Sandy L Richardson; Xiongwei Zhu; Mark A Smith; Brian D Hoit; Hyoung-Gon Lee
Journal:  Int J Clin Exp Pathol       Date:  2011-06-07

Review 5.  Assessing Cardiac Metabolism: A Scientific Statement From the American Heart Association.

Authors:  Heinrich Taegtmeyer; Martin E Young; Gary D Lopaschuk; E Dale Abel; Henri Brunengraber; Victor Darley-Usmar; Christine Des Rosiers; Robert Gerszten; Jan F Glatz; Julian L Griffin; Robert J Gropler; Hermann-Georg Holzhuetter; Jorge R Kizer; E Douglas Lewandowski; Craig R Malloy; Stefan Neubauer; Linda R Peterson; Michael A Portman; Fabio A Recchia; Jennifer E Van Eyk; Thomas J Wang
Journal:  Circ Res       Date:  2016-03-24       Impact factor: 17.367

6.  A dilated cardiomyopathy mutation blunts adrenergic response and induces contractile dysfunction under chronic angiotensin II stress.

Authors:  Ross Wilkinson; Weihua Song; Natalia Smoktunowicz; Steven Marston
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-10-02       Impact factor: 4.733

7.  Acute Catecholamine Exposure Causes Reversible Myocyte Injury Without Cardiac Regeneration.

Authors:  Markus Wallner; Jason M Duran; Sadia Mohsin; Constantine D Troupes; Davy Vanhoutte; Giulia Borghetti; Ronald J Vagnozzi; Polina Gross; Daohai Yu; Danielle M Trappanese; Hajime Kubo; Amir Toib; Thomas E Sharp; Shavonn C Harper; Michael A Volkert; Timothy Starosta; Eric A Feldsott; Remus M Berretta; Tao Wang; Mary F Barbe; Jeffrey D Molkentin; Steven R Houser
Journal:  Circ Res       Date:  2016-07-26       Impact factor: 17.367

8.  Isoproterenol-induced myocardial injury and diastolic dysfunction in mice: structural and functional correlates.

Authors:  Wesley W Brooks; Chester H Conrad
Journal:  Comp Med       Date:  2009-08       Impact factor: 0.982

Review 9.  Role of Beta-adrenergic Receptors and Sirtuin Signaling in the Heart During Aging, Heart Failure, and Adaptation to Stress.

Authors:  Regina Celia Spadari; Claudia Cavadas; Ana Elisa T Saturi de Carvalho; Daniela Ortolani; Andre Luiz de Moura; Paula Frizera Vassalo
Journal:  Cell Mol Neurobiol       Date:  2017-10-24       Impact factor: 5.046

10.  Cardiovascular response to beta-adrenergic blockade or activation in 23 inbred mouse strains.

Authors:  Corinne Berthonneche; Bastian Peter; Fanny Schüpfer; Pamela Hayoz; Zoltán Kutalik; Hugues Abriel; Thierry Pedrazzini; Jacques S Beckmann; Sven Bergmann; Fabienne Maurer
Journal:  PLoS One       Date:  2009-08-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.